No association between BRCA1 immunohistochemical expression and tumor grade, stage or overall survival in platinum-treated epithelial ovarian cancer patients

Asian Pacific Journal of Cancer Prevention

Volumn 15, Issue 10, 2014, Pages 4275-4279

  Shawky, Abd El Aty ^a   El Hafez, Amal Abd ^a   El Tantawy, Dina ^a   Hamdy, Rasha ^a  

^a MANSOURA UNIVERSITY   (Egypt)

Author keywords

BRCA1; Histological subtype; Immunohistochemistry; Ovarian carcinoma; Overall survival

Indexed keywords

BRCA1 PROTEIN; BRCA1 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; BIOSYNTHESIS; CANCER GRADING; DISEASE FREE SURVIVAL; FEMALE; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; MIDDLE AGED; MORTALITY; NEOPLASM; OVARY TUMOR; PATHOLOGY; RETROSPECTIVE STUDY; SURVIVAL RATE; YOUNG ADULT;

ADULT; BRCA1 PROTEIN; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM GRADING; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84903514251     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2014.15.10.4275     Document Type: Article

References (34)

1. Aida H, Takakuwa K, Nagata H, et al (1998). Clinical features of ovarian cancer in Japanese women with germline mutations of BRCA1. Clin Cancer Res, 4, 235-40.
2. Altekruse S, Kosary C, Krapcho M, et al (eds). (2010). SEER Cancer Statistics Review, 1975-2007, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/ csr/1975_2007/.
3. Ben-David Y, Chetrit A, Hirsh-Yechezkel G, et al (2002). Effect of BRCA mutations on the length of survival in epithelial ovarian tumors. J Clin Oncol, 20, 463-6.
4. Bolton KL, Chenevix-Trench G, Goh C, et al (2012). Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. JAMA, 307, 382-90.
5. Boyd J, Sonoda Y, Federici MG, et al (2000). Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. JAMA, 283, 2260-5.
6. Carser JE, Quinn JE, Michie CO, et al (2011). BRCA1 is both a prognostic and predictive biomarker of response to chemotherapy in sporadic epithelial ovarian cancer. Gynecol Oncol, 123, 492-8.
7. Chetrit A, Hirsh-Yechezkel G, Ben-David Y, et al (2008). Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer. J Clin Oncol, 26, 20-5.
8. Gowen LC, Avrutskaya AV, Latour AM, Koller BH, Leadon SA (1998). RCA1 required for transcription-coupled repair of oxidative NA damage. Science, 281, 1009-12.
9. Han Y, Wang XB, Xiao N, Liu ZD (2013). mRNA expression and clinical significance of ERCC1, BRCA1, RRM1, TYMS and TUBB3 in postoperative patients with non-small cell lung cancer. Asian Pac J Cancer Prev, 14, 2987-90.
10. Hasan TN, Shafi G, Syed NA, et al (2013). Lack of association of BRCA1 and BRCA2 variants with breast cancer in an ethnic population of Saudi Arabia, an emerging high-risk area. Asian Pac J Cancer Prev, 14, 5671-4.
11. Ji T, Zheng ZG, Wang FM, et al (2014). Differential microRNA expression by solexa sequencing in the sera of ovarian cancer patients. Asian Pac J Cancer Prev, 15, 1739-43.
12. Johannsson OT, Ranstam J, Borg A, Olsson H (1998). Survival of BRCA1 breast and ovarian cancer patients: a populationbased study from southern Sweden. J Clin Oncol, 16, 397-404.
13. Joo JG, Ladi S, Nagy BZ, Langmár Z (2011). Management of hereditary ovarian cancer. Orv Hetil, 152, 1596-608. (Pubmed abstract).
14. Kooshyar MM, Nassiri M, Mahdavi M, Doosti M, Parizadeh A (2013). Identification of germline BRCA1 mutations among breast cancer families in Northeastern Iran. Asian Pac J Cancer Prev, 14, 4339-45.
15. Lan VTT, Thuan TB, Thu DM, et al (2013). Methylation profile of BRCA1, RASSF1A and ER in Vietnamese women with ovarian cancer. Asian Pac J Cancer Prev, 14, 7713-8.
16. Lesnock JL, Darcy KM, Tian C, et al (2013). BRCA1 expression and improved survival in ovarian cancer patients treated with intraperitoneal cisplatin and paclitaxel: a gynecologic oncology group study. Br J Cancer, 108, 1231-7.
17. Li FY, Ren XB, Xie XY, Zhang J (2013). Meta-analysis of excision repair cross-complementation group 1 (ERCC1) association with response to platinum-based chemotherapy in ovarian cancer. Asian Pac J Cancer Prev, 14, 7203-6.
18. Lorusso D, Cirillo F, Mancini M, et al (2013). The different impact of BRCA mutations on the survival of epithelial ovarian cancer patients: a retrospective single-center experience. Oncology, 85, 122-7.
19. Mahdi KM, Nassiri MR, Nasiri K (2013). Hereditary genes and SNPs associated with breast cancer. Asian Pac J Cancer Prev, 14, 3403-9.
20. O'Donovan PJ, Livingston DM (2010). BRCA1 and BRCA2: breast/ovarian cancer susceptibility gene products and participants in DNA double-strand break repair. Carcinogenesis, 31, 961-7.
21. Pharoah PD, Easton DF, Stockton DL, Gayther S, Ponder BA (1999). Survival in familial, BRCA1-associated, and BRCA2-associated epithelial ovarian cancer. Cancer Res, 59, 868-71.
22. Prat J, Rib A, Gallardo A (2005) Hereditary ovarian cancer. Hum Pathol, 36, 861-70.
23. Quinn JE, Carser JE, James CR, Kennedy RD, Harkin DP (2009). BRCA1 and implications for response to chemotherapy in ovarian cancer. Gynecol Oncol, 113, 134-42.
24. Radosa MP, Häfner N, Camara O, et al (2011). Loss of BRCA1 protein expression as indicator of the BRCAness phenotype is associated with favorable overall survival after complete resection of sporadic ovarian cancer. Int J Gynecol Cancer, 21, 1399-406.
25. Rubin SC, Benjamin I, Behbakht K, et al (1996). Clinical and pathological features of ovarian cancer in women with germline mutations of BRCA1. N Engl J Med, 335, 1413-6.
26. Sirisabya N, Manchana T, Termrungreunglert W, et al (2007). Prevalence of BRCA1 Expression in Epithelial Ovarian Cancer: Immunohistochemical Study. J Med Assoc Thai, 90, 9-14.
27. Skytte AB, Waldenstorm M, Rasmussen AA, et al (2011). Identification of BRCA1-deficient ovarian cancers. Acta Obstet Gynecol Scand, 90, 593-9. (Pubmed abstract).
28. Sowter HM, Ashworth A (2005). BRCA1 and BRCA2 as ovarian cancer susceptibility genes. Carcinogenesis, 26, 1651-6.
29. Swisher E (2003). Ovarian cancer associated with inherited mutations in BRCA1. Curr Women Health Rep, 3, 27-32.
30. Tutt A, Ashworth A (2002). The relationship between the roles of BRCA genes in DNA repair and cancer predisposition. Trends Mol Med, 8, 571-6.
31. Venkitaraman AR (2002). Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell, 108, 171-82.
32. Werness BA, Ramus SJ, DiCioccio RA, et al (2004). Histopathology, FIGO stage, and BRCA mutation status of ovarian cancers from the Gilda Radner familial ovarian cancer registry. Int J Gynecol Pathol, 23, 29-34.
33. Wysham WZ, Mhawech-Fauceglia P, Li H, et al (2012). BRCAness profile of sporadic ovarian cancer predicts disease recurrence. PLoS One, 7, 30042.
34. Yang D, Khan S, Sun Y, et al (2011). Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. JAMA, 306, 1557-65.